Graham Svoronos

Insider profile

Currently holds positions in PTC Therapeutics Inc, Xenon Pharmaceuticals Inc and Global Blood Therapeutics Inc

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return -4% 8.2% 15.1%
Success rate 77% 68% 82%
Transactions
8 25% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director PTC Therapeutics Inc June 13, 2016 -
Independent Director Xenon Pharmaceuticals Inc Sept. 27, 2016 -
Independent Director Global Blood Therapeutics Inc Dec. 19, 2018 -
Director Endocyte Inc None -
Independent Director Medivation Inc Dec. 1, 2014 - Sept. 28, 2016
Interim Chief Commercial Officer, Director Medivation Inc July 10, 2014 - Dec. 1, 2014
Independent Director Medivation Inc April 1, 2013 - July 10, 2014
Graham Svoronos's trades of Xenon Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
494.98
Quantity 72,705
Value US$715,107
US ACELYRIN Inc (SLRN)
Transaction date
Purchase
Price
130.27
Quantity 66,634 +16.5%
Value US$1,299,955
Transaction date
Sale
Price
27.20
Quantity 738 -2.5%
Value US$20,074
Transaction date
Sale
Price
38.53
Quantity 510 -1.9%
Value US$19,648
Transaction date
Sale
Price
41.89
Quantity 365 -1.3%
Value US$15,288
Transaction date
Sale
Price
56.96
Quantity 506 -1.8%
Value US$28,820
Transaction date
Sale
Price
48.36
Quantity 364 -1.4%
Value US$17,603
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-24 2023-08-24
PrS Proposed sale
72,705
494.98
US$715,107 		72,705 494.98 US$715,107
2023-08-24 2023-08-24
S Sale
53,536 +5.2%
111.73
US$3,887,645 		53,536 +5.2% 111.73 US$3,887,645
2023-05-11 2023-05-09
US ACELYRIN Inc (SLRN)
B Purchase
66,634 +16.5%
130.27
US$1,299,955 		66,634 +16.5% 130.27 US$1,299,955
2022-06-22 2022-06-21
PlS Planned sale
1,908 -26.2%
27.24
US$51,983 		1,908 -26.2% 27.24 US$51,983
2022-06-10 2022-06-09
S Sale
738 -2.5%
27.20
US$20,074 		738 -2.5% 27.20 US$20,074
2022-05-18 2022-05-16
B Purchase
30,000 +150.0%
0.85
US$25,578 		30,000 +150.0% 0.85 US$25,578
2022-01-11 2022-01-07
S Sale
510 -1.9%
38.53
US$19,648 		510 -1.9% 38.53 US$19,648
2021-06-21 2021-06-18
PlS Planned sale
1,609 -30.4%
36.54
US$58,793 		1,609 -30.4% 36.54 US$58,793
2021-06-11 2021-06-09
S Sale
365 -1.3%
41.89
US$15,288 		365 -1.3% 41.89 US$15,288
2021-04-01 2021-03-31
B Purchase
20,000 New position
10.02
US$200,338 		20,000 New position 10.02 US$200,338
2021-02-02 2021-02-01
S Sale
506 -1.8%
56.96
US$28,820 		506 -1.8% 56.96 US$28,820
2020-06-19 2020-06-19
PlS Planned sale
881 -28.1%
64.42
US$56,750 		881 -28.1% 64.42 US$56,750
2020-06-19 2020-06-19
PlS Planned sale
1,663 -34.6%
63.69
US$105,913 		1,663 -34.6% 63.69 US$105,913
2020-06-12 2020-06-11
S Sale
364 -1.4%
48.36
US$17,603 		364 -1.4% 48.36 US$17,603